Porcine reproductive and respiratory syndrome vaccine

• US 5,866,401 A
• Filed: 02/24/1997
• Issued: 02/02/1999
• Est. Priority Date: 03/01/1996
• Status: Expired due to Term

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Hesse, Richard A.
• Primary Examiner(s): Knode, Marian C.
• Assistant Examiner(s): LEE, DATQUAN HUU
• Application Number:
  US08/805,087
• Time in Patent Office: 708 Days
• Field of Search: 424/204.1, 424/199.1, 435/235.1, 435/236, 435/237, 435/238, 435/240.2
• US Class Current: 435/237
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/55 characterised by the host/recipient, e.g. newborn with maternal antibodies
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention discloses a vaccine and methods for the treatment of porcine reproductive and respiratory syndrome. The vaccine is derived from the viral agent NEB-l-P94, deposited at the American Type Culture Collection under accession number VR-2525.

Further, the invention discloses a vaccine virus with phenotypic characteristics which can be distinguished from wild type PRRS virus.

Claims

1. A vaccine suitable for immunizing swine against porcine reproductive and respiratory syndrome comprising a PRRS virus having all the identifying characteristics of the isolate NEB- 1 -P94, deposited at the American Type Culture Collection under the accession number VR-2525.

2. The vaccine of claim 1 containing an amount of 10⁴.0 to 10⁹.0 TCID⁵⁰ of the PRRS virus per ml.

3. A method of protecting a pig from clinical signs of disease caused by the porcine reproductive and respiratory syndrome virus comprising administering an effective amount of the vaccine of claim 1 to a pig.

4. The method of claim 3 wherein said vaccine is administered intramuscularly, intradermally, intravenously, or subcutaneously.